Showing results (2161-2170 of 3,160) with videos related to

Sort By:
Pageof 316
Neuro-Oncology|March 6, 2014
Implications of bevacizumab discontinuation in adults with recurrent glioblastomaMark D Anderson, Mohamed A Hamza, Kenneth R Hess, et al.
Neuro-Oncology|March 4, 2008
Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumorsStaci D Arnold, Leslie M Forman, Bart D Brigidi, et al.
Neuro-Oncology|November 13, 2018
Novel methods to diagnose leptomeningeal metastases in breast cancerLindsay Angus, John W M Martens, Martin J van den Bent, et al.
Neuro-Oncology|November 13, 2018
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastomaTanja Eisemann, Barbara Costa, Patrick N Harter, et al.
Neuro-Oncology|October 23, 2018
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomasBill H Diplas, Heng Liu, Rui Yang, et al.
Neuro-Oncology|February 17, 2017
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment responseQuintino Giorgio D'Alessandris, Mauro Biffoni, Maurizio Martini, et al.
Neuro-Oncology|April 4, 2017
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapyTiffany R Hodges, Martina Ott, Joanne Xiu, et al.
Neuro-Oncology|April 6, 2017
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastomaRobert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, et al.
Neuro-Oncology|January 14, 2017
SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomasJulien Boetto, Franck Bielle, Marc Sanson, et al.
Neuro-Oncology|January 14, 2017
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomasYu Sun, John A Alberta, Catherine Pilarz, et al.
Pageof 316